Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-601 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT04670679Phase 1Completed
- Sponsor
- Erasca
- Start
- Dec 2020
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ERAS-601 in solid tumor, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and 1 more (5 arms), sponsored by Erasca. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and 6 more. Started Dec 2020; status: completed.
02
Drugs
ERAS-601
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04670679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670679.